No Prescription |
 |
 | ||
|
FUCIDIN Fusidin Leo |
|
| ||
No Prescription » Prescription Drugs 8 » FUCIDIN Fusidin Leo This medicine contains the active ingredient fusidic acid which is an antibacterial agent used to treat a number of bacterial skin infections.It works in the bacterial cell by preventing the production of essential proteins necessary for the growth and survival of the bacteria. It is effective against several bacterial species and used in the treatment of infections such as impetigo (characterised by blistering and yellowish-brown crusting of the skin) whitlow (paronchya) and inflammation of hair follicles (sycosis). It is also used to treat eczema or dermatitis that has become infected (secondary infections).What is it used for?Bacterial skin infections Buy FUCIDIN Fusidin Leo and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About FUCIDIN Fusidin Leo: Product Type: Prescription Drugs 8 FUCIDIN ( Fusidin Leo Generic Fusidic Acid ) FUCIDIN (Fusidin Leo Generic Fusidic Acid) Fusidin Leo Generic Fusidic Acid 15gm Ointment Tube 15gm Ointment 3 Tubes 20mg Cream 10 gm 20 mg 5gm Cream 20 mg 2 x 5gm Cream 20 mg 4 x 5gm Cream Fusidin Leo Generic Fusidic Acid FUCIDIN
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
